$9.58
0.10% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock price

$9.58
+0.23 2.46% 1M
-5.34 35.79% 6M
-8.37 46.63% YTD
-9.61 50.08% 1Y
-23.63 71.15% 3Y
-31.88 76.89% 5Y
-20.87 68.54% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.01 0.10%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $474.64m
Enterprise Value $364.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.33
P/S ratio (TTM) P/S ratio 5.63
P/B ratio (TTM) P/B ratio 1.57
Revenue growth (TTM) Revenue growth -15.14%
Revenue (TTM) Revenue $84.33m
EBIT (operating result TTM) EBIT $-243.78m
Free Cash Flow (TTM) Free Cash Flow $-184.74m
Cash position $255.46m
EPS (TTM) EPS $-5.03
P/E forward negative
P/S forward 5.48
EV/Sales forward 4.21
Short interest 12.96%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a REGENXBIO, Inc. forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
100%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
84 84
15% 15%
100%
- Direct Costs 55 55
2% 2%
65%
29 29
33% 33%
35%
- Selling and Administrative Expenses 59 59
11% 11%
70%
- Research and Development Expense 197 197
11% 11%
234%
-227 -227
7% 7%
-269%
- Depreciation and Amortization 17 17
3% 3%
20%
EBIT (Operating Income) EBIT -244 -244
7% 7%
-289%
Net Profit -239 -239
8% 8%
-283%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Neutral
PRNewsWire
8 days ago
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients  trea...
Neutral
PRNewsWire
12 days ago
-       Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.
Neutral
Seeking Alpha
19 days ago
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 344
Founded 2008
Website www.regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today